Dimension Therapeutics announced it has entered into a pharma deal with Bayer HealthCare for the development and commercialization of a novel gene therapy for the treatment of hemophilia A.
Dimension will receive an upfront payment of $20 million and will be eligible for potential development and commercialization milestone payments of up to $232 million.
Dimension will be responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer.
Depending on the results of the Phase 1/2a clinical trial, Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A.
Dimension is eligible to receive tiered royalties based on product sales.
Hemophilia is a rare bleeding disorder in which patients produce little or no clotting factor, a protein needed for normal blood clotting, which can cause life threatening bleeding.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Bayer
Report: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity